Systematic Review of Emerging Antifungal Agents Against Candida auris

Study Background and Research Question

Invasive infections caused by Candida auris have become a significant clinical challenge, particularly in critically ill and immunocompromised patients. The organism's remarkable resistance to traditional antifungal classes—azoles, polyenes, and echinocandins—has resulted in mortality rates exceeding 50% in some populations. Complicating control efforts, C. auris demonstrates the ability to persist on skin and surfaces, form biofilms, and spread within healthcare environments. The central research question addressed by Treviño-Rangel et al. is: What is the current evidence for efficacy and pharmacological innovation among antifungal agents in development for C. auris, and how might these agents overcome the limitations of existing therapies?

Key Innovation from the Reference Study

The systematic review provides a comprehensive assessment of the antifungal pipeline, focusing on both new formulations within established classes and first-in-class agents with novel mechanisms. Importantly, the review highlights the emergence of next-generation tetrazoles—such as Oteseconazole (VT-1161)—and other compounds that show enhanced selectivity and potency against C. auris, including strains resistant to fluconazole and echinocandins. This focus on innovative molecular scaffolds is critical, as it addresses the urgent need for agents with broad-spectrum efficacy but reduced host toxicity and drug interaction risks.

Methods and Experimental Design Insights

The authors conducted a systematic literature search across MEDLINE, EMBASE, Web of Science, and Scopus, identifying studies up to June 27, 2022. A PRISMA-compliant strategy was used to screen 592 articles, ultimately including 27 relevant studies for qualitative synthesis. The review collates data on in vitro susceptibility (MIC determinations), in vivo efficacy in neutropenic animal models of candidemia, and pharmacodynamic parameters for each investigational antifungal, providing a robust framework for comparative analysis. The focus is on agents with reported activity against C. auris, including those with novel mechanisms: tetrazoles (quilseconazole, Oteseconazole, VT-1598), the triterpenoid ibrexafungerp, manogepix/fosmanogepix, and others.

Core Findings and Why They Matter

The review documents that several investigational agents demonstrate substantially improved in vitro and in vivo activity against C. auris compared to legacy antifungals. For example, manogepix/fosmanogepix showed a low MIC₉₀ (0.03 mg/L), while ibrexafungerp and rezafungin exhibited promising activity (MIC₉₀ of 1 mg/L and 0.25 mg/L, respectively). Tetrazole compounds, including Oteseconazole (VT-1161), are specifically noted for their enhanced selectivity for fungal CYP51, which is critical for ergosterol biosynthesis and membrane integrity in Candida species. This selectivity translates to potent growth inhibition—including in fluconazole-resistant isolates—while minimizing off-target effects on human CYP enzymes, thus reducing the risk of drug-drug interactions. In neutropenic animal models, these agents led to significant reductions in tissue fungal burden and improved survival, supporting their potential for clinical translation.

Protocol Parameters

• In vitro MIC assessment: For investigational tetrazoles, MICs against C. auris and other Candida spp. are typically determined across a range of 0.00625–0.1 μg/mL, as supported by both the systematic review and product information.
• Animal model validation: Neutropenic murine models of candidemia are preferred to evaluate survival endpoints and tissue fungal burden reduction.
• Dosing considerations: For translational relevance, plasma drug levels should be maintained above the MIC for the target organism, particularly in prevention of recurrent vulvovaginal candidiasis protocols.
• Compound handling: Oteseconazole is soluble at ≥50 mg/mL in DMSO or ethanol, but insoluble in water; short-term storage at -20°C is recommended for solution stability.

Comparison with Existing Internal Articles

Internal articles such as "Oteseconazole (VT-1161): Enhanced Workflows for Candida Research" and "Oteseconazole (VT-1161): Precision Antifungal Targeting" provide practical laboratory insights and protocol troubleshooting for researchers utilizing Oteseconazole in antifungal assays. These resources reinforce the reference study's findings regarding Oteseconazole's selectivity for fungal CYP51 and sub-microgram MICs against a spectrum of Candida species, including fluconazole-resistant strains. Additionally, they detail practical workflow optimizations—such as DMSO solubilization and dosing strategies—to ensure experimental rigor, complementing the preclinical efficacy data summarized in the systematic review.

Limitations and Transferability

Despite the promise of these investigational agents, several limitations are acknowledged by the review. Most efficacy data are derived from in vitro susceptibility testing and animal models, with limited clinical trial data available for C. auris-specific infections. The genetic and phenotypic variability among C. auris clades may also impact transferability of results across geographic regions. Furthermore, the emergence of pan-resistant isolates underscores the need for ongoing surveillance and combination therapy strategies. Nevertheless, the systematic review provides a critical foundation for prioritizing agents—such as Oteseconazole and other tetrazoles—for further translational and clinical evaluation.

Research Support Resources

For researchers seeking to explore antifungal agent efficacy against C. auris and related Candida species, Oteseconazole (VT-1161) (SKU BA1665) is available as a validated research compound. Its high selectivity, potent growth inhibition at low MICs, and favorable pharmacological profile make it suitable for in vitro and preclinical workflows, particularly in studies of fluconazole-resistant Candida and recurrent vulvovaginal candidiasis. Protocol guidance, solubility information, and best-practice recommendations are provided in both the product documentation and specialized internal articles. Researchers can integrate Oteseconazole into their experimental designs to support robust, reproducible antifungal research.